tirzepatide insurance approval Approval: Timeline & Alternatives Now that shortages of semaglutide

Wegovy (semaglutide) injection, for subcutaneous use: prescribing information

After the initial weight loss period, patients were split into two groups: Group 1 Continued tirzepatide: Lost an additional 5.5% of body weight over the next 52 weeks Group 2 Switched to placebo (stopped tirzepatide): Regained 14% of their body weight over the next 52 weeks A follow-up analysis published in JAMA Internal Medicine in November 2025 added an important detail: 82.5% of participants who stopped tirzepatide regained at least 25% of their lost weight within one year

Long-term storage (months to years): Freeze the lyophilized vial at 80 C (112 F)

John Sharretts, the director of the Division of Diabetes, Lipid Disorders and Obesity for the FDAs Center for Drug Evaluation and Research, said in a statement

For additional context on evaluating providers, our best peptide vendors guide provides a broader framework